Email: cspc@cspc.cn
News
News Center
Jun. 02
2025
JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER
May. 19
JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
CPO301 GRANTED THE THIRD FAST TRACK DESIGNATION BY U.S. FDA FOR THE TREATMENT OF ADULT PATIENTS WITH NSCLC
May. 15
EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION
May. 12
VONOPRAZAN FUMARATE TABLETS OBTAINS DRUG REGISTRATION APPROVAL
May. 09
SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
